BYN-001 targets IL-25, an emerging upstream regulator of Type 2 inflammation implicated in atopic dermatitis, and leverages half-life extension technology Bionyra is building a broad IL-25 franchise, including a preclinical IL-25×IL-13 multispecific antibody and future combination opportunities PARIS and BOSTON, September 10th, 2026 – Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics designed to […]
Read MoreMore TagBionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases
Series A co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures Sofinnova Partners seed financed and co-founded Bionyra alongside Frédéric Marrache, MD, PhD, CEO of the company Pipeline includes clinical and IND stage mono and multispecific antibodies with half-life extension engineering […]
Read MoreMore Tag